Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan
Intestinal Research · 31.10.2026 · 24 (4) · 767-775
DOI: 10.5217/ir.2025.00176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Intestinal Research, erschienen am 31.10.2026. Verfasst von Ichiro Mizushima und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Foundation for Applied Enzymology.
Abstract (Originalsprache)
Background/Aims: Randomized controlled trials have confirmed the efficacy and safety of mirikizumab, an anti-interleukin-23p19 monoclonal antibody, for moderate-to-severe active ulcerative colitis (UC). However, there are no real-world data on the efficacy and safety of mirikizumab for UC as maintenance therapy, especially in difficult-to-treat inflammatory bowel disease (DTT-IBD). This study aimed to evaluate the long-term efficacy and safety of mirikizumab in patients with UC of DTT-IBD.
Methods
This was a single-center retrospective observational study involving adult patients with UC who received mirikizumab between January 2023 and April 2025 and met the criteria for DTT-IBD (e.g., failure of biologics and advanced small molecule drugs with at least 2 different mechanisms of action). The primary outcome was the clinical response at week 52. Secondary outcomes included steroid-free clinical remission within 52 weeks and the persistency of mirikizumab use. Adverse events were also recorded.
Results
Thirty-two patients were included in this study. The median 2-item patient-reported outcome score at baseline was 3 (interquartile range, 2–4). The proportion of patients with a clinical response at week 52 was 33.3% (95% confidence interval, 14.6%–57.0%). Steroid-free clinical remission was achieved in 26.7% (95% confidence interval, 12.3%–45.9%) of the patients. The cumulative continuous rate of mirikizumab use at week 52 was approximately 60%. Only 1 patient developed a serious adverse event requiring hospitalization (pneumonia), and mirikizumab was successfully resumed after recovery.
Conclusions
The present study demonstrated real-world data regarding maintenance therapy with mirikizumab for UC among patients with DTT-IBD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. yyyy1y8yyyy@keio.jp.
- Department of Multidimensional Analysis of Gastrointestinal Biology, The Sakaguchi Laboratory, Keio University School of Medicine, Tokyo, Japan.
- Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Tokyo, Japan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. takagast@keio.jp.
Förderung
- Japan Society for the Promotion of Science
- Japan Foundation for Applied Enzymology
Zitieren
APA
Mizushima, I., Yoshimatsu, Y., Kiyohara, H., Sugimoto, S., Sujino, T., Takabayashi, K., Mikami, Y., & Kanai, T. (2026). Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan. Intestinal Research, 24(4), 767-775. https://doi.org/10.5217/ir.2025.00176
Vancouver
Mizushima I, Yoshimatsu Y, Kiyohara H, Sugimoto S, Sujino T, Takabayashi K, et al. Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan. Intestinal Research. 2026;24(4):767-775. doi:10.5217/ir.2025.00176
BibTeX
@article{Mizushima2026,
author = {Mizushima, Ichiro and Yoshimatsu, Yusuke and Kiyohara, Hiroki and Sugimoto, Shinya and Sujino, Tomohisa and Takabayashi, Kaoru and Mikami, Yohei and Kanai, Takanori},
title = {Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan},
journal = {Intestinal Research},
year = {2026},
volume = {24},
number = {4},
pages = {767--775},
doi = {10.5217/ir.2025.00176}
}
EUVIMED